Abstract
Introduction
The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination.
Methods
A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model.
Results
We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients.
Conclusions
TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.
Keywords: COVID-19, Cancer, Thoracic, NSCLC, TERAVOLT, Registry
Introduction
The Thoracic Cancers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) is a global observational study of patients with thoracic malignancies and a diagnosis of COVID-19. Prior analysis of mortality was 24.2% to 33%.1,2
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.529 (Omicron) variant was classified as a Variant of Concern by the WHO in November 2021.3 Omicron was found to have the ability to evade existing SARS-CoV-2–neutralizing antibodies.4 Nevertheless, the first Omicron-related data from South Africa had improved patient outcomes compared with earlier waves.5
COVID-19 vaccine efficacy seems to wane over time, with the BNT162b2 (Pfizer-BioNTech) vaccine falling from 88% effectiveness after full vaccination to 47% after five months.6 SARS-CoV-2 antibody response in patients treated with anticancer agents was found to decrease in effectiveness at three months after the second vaccine dose, with a strong serologic response occurring after a third dose of the vaccine.7 A prospective study of humoral responses to the SARS-CoV-2 vaccine in patients with thoracic cancer found a third vaccination resulted in an 88% seroconversion.8
In this study, we leveraged TERAVOLT to assess mortality and cancer treatment-related delays from the recent fourth COVID-19 wave. In addition, we analyzed the effect of vaccination with or without a booster on COVID-19-related outcomes.
Materials and Methods
A prospective, multicenter observational study was conducted. A total of 28 institutions from four continents contributed data from January 14, 2022, to February 4, 2022. Data were entered into a deidentified REDCap (Research Electronic Data Capture) database, with each institution assigned a unique number.
Main eligibility criteria were patients with any thoracic cancer (NSCLC, SCLC, mesothelioma, thymic epithelial tumors, and other pulmonary neuroendocrine neoplasms) and a laboratory-confirmed diagnosis of COVID-19 on or after November 1, 2021. Patients with any stage of cancer diagnosis were eligible, including those actively receiving anticancer treatment and those in clinical follow-up.
Data collected included the following: demographics, oncologic history, comorbidities, COVID-19 symptoms and treatment, and clinical outcomes. For this analysis, new data were collected on COVID-19 vaccination and booster status, and, if known, type of variant. Primary end points were as follows: (1) mortality; (2) hospitalization; (3) symptomatic COVID-19 defined as fever, pneumonitis, or dyspnea; (4) almost asymptomatic COVID-19 infection, defined as upper respiratory symptoms only; or (5) asymptomatic COVID-19 infection. Delay in cancer treatment due to COVID-19 was also collected.
Statistical Analysis
Descriptive statistics of patient demographics (e.g., age, sex) and clinical characteristics (e.g., comorbidities, anticancer therapy) were reported as frequencies (proportions) for categorical variables and median (interquartile range) for continuous variables. Summary measures for association between demographic and clinical characteristics, vaccination, and outcomes were assessed by univariable logistic models; the association with risk of hospitalization or death was also assessed with multivariable logistic models. Results are given as ORs with 95% confidence intervals (CIs). In multivariable analysis of factors associated with risk of death, we included all factors known to be associated with COVID-19 outcomes in general patient populations.9 The study analysis was based on a convenience sample; no power analysis was done to calculate sample size.
Results
We enrolled 346 patients, with 182 (53.3%) from Europe, 150 (43.1%) from North America, 10 (2.9%) from South America, and 6 (1.7%) from Asia (Table 1). Almost all patients (98.0%) had at least 14 days of follow-up after their COVID-19 diagnosis. Median age was 65 years, 52.3% were female, and 74.2% were current or former smokers. At least one comorbidity was present in 234 patients (67.6%).
Table 1.
Demographic and Clinical Characteristics
| Patient Characteristics | All Patients (N = 346) |
|---|---|
| Continent | |
| Europe | 181/346 (52%) |
| North America | 150/346 (43%) |
| South America | 9/346 (3%) |
| Asia | 6/346 (2%) |
| Age, y (median) | |
| ≥65 | 185/346 (53%) |
| <65 | 161/346 (46%) ` |
| BMI | |
| Median | 25.0 |
| Sex | |
| Female | 181/346 (52%) |
| Male | 165/346 (48%) |
| Race | |
| White | 221/304 (73%) |
| Black or African American | 46/304 (15%) |
| Asian | 15/304 (5%) |
| Other | 22/304 (7%) |
| Smoking status | |
| Current | 70/340 (20%) |
| Former | 186/340 (55%) |
| Never | 84/340 (25%) |
| ECOG | |
| 0, 1 | 271/336 (81%) |
| ≥2 | 65/336 (19%) |
| Comorbidity | |
| None | 112/346 (32%) |
| Any | 234/346 (68%) |
| COPD | 96/346 (28%) |
| Diabetes | 13/346 (4%) |
| Hypertension | 139/346 (40%) |
| Baseline steroid use (>10 mg of prednisone or equivalent) | |
| Yes | 41/346 (12%) |
| No | 305/346 (88%) |
| Time since cancer diagnosis | |
| ≤12 mo | 143/346 (41%) |
| >12 mo | 203/346 (59%) |
| Diagnosis | |
| NSCLCs | 296/346 (85%) |
| SCLC | 32/346 (9%) |
| Mesothelioma | 9/346 (3%) |
| Thymic carcinoma | 2/346 (0.6%) |
| Thymoma | 3/346 (0.9%) |
| Carcinoid/neuroendocrine | 4/346 (1.2%) |
| Cancer stage at COVID-19 diagnosis | |
| I, II, or III | 98/345 (28%) |
| IV | 247/345 (72%) |
| Cancer treatment at time of COVID-19 diagnosis (multiple allowed) | |
| None | 100 (29%) |
| Cytotoxic chemotherapy | 107 (31%) |
| Immunotherapy | 96 (28%) |
| Targeted therapy | 69 (20%) |
| Radiotherapy | 14 (4%) |
| Other | 16 (5%) |
| COVID-19 variant | |
| Unknown/not reported | 267/346 (77%) |
| Of Known | |
| Omicron | 65/79 (82%) |
| Delta | 14/79 (18%) |
| Vaccination status | |
| Unvaccinated | 48/337 (14%) |
| Vaccinated without booster | 133/337 (40%) |
| Vaccinated with booster | 156/337 (46%) |
BMI, body mass index; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; ECOG, Eastern Cooperative Oncology Group.
Regarding cancer characteristics, 143 (41.3%) had been diagnosed within 1 year of COVID-19 infection. NSCLC was the predominant diagnosis (85.6%), and 71.4% had stage IV disease at time of COVID-19 diagnosis. Most (71.1%) were receiving cancer treatment at the time of COVID-19 diagnosis, which included cytotoxic chemotherapy (30.9%), immunotherapy (27.7%), targeted therapy (19.9%), and radiation (4.0%).
COVID-19 variant was unknown for 69.7%; for those known, omicron was present in 82.3% (65 of 79) and delta in 18% (14 of 29). Most patients were vaccinated for COVID-19 (289 of 346, 83.5%) at the time of COVID-19 diagnosis, with 133 (38%) receiving a vaccine without booster, 156 (45.1%) receiving vaccine with a booster, and 48 patients (14%) being unvaccinated. Most patients received no therapy for COVID-19 (59.2%), such as steroid, antiviral, or antibody infusion.
Overall mortality was 3.2% (Table 2). Other COVID-19 outcomes included asymptomatic infection (17.3%), mild symptoms of upper respiratory symptoms only (37.9%), moderate symptoms of fever, pneumonitis, or shortness of breath (20.5%), or admission to hospital (19.9%). A delay in cancer care was experienced in 56.4% of the patients.
Table 2.
COVID-19–Related Outcomes
| Outcome Measures | All Patients (N = 346) |
|---|---|
| ≥14 d of follow-up from COVID-19 diagnosis | |
| Yes | 339/346 (98%) |
| No | 7/346 (2%) |
| Delay in cancer treatment due to COVID-19 diagnosis | |
| Yes | 195/343 (57%) |
| No | 148/343 (43%) |
| Worst COVID-19 outcome patient encountered | |
| Asymptomatic | 60/342 (18%) |
| Almost asymptomatic (upper respiratory symptoms only) | 131/342 (38%) |
| Fever, pneumonitis, or dyspnea | 71/342 (21%) |
| Admission to hospital | 69/342 (20%) |
| Death | 11/342 (3%) |
COVID-19, coronavirus disease 2019.
At multivariate analysis, COVID-19 vaccination with booster had a protective effect on hospitalization or death compared with no vaccination (OR = 0.30, CI: 0.15–0.57, p = 0.01; Table 3). Vaccination without booster had an OR of 0.64 (CI: 0.33–1.24, p = 0.19). Eastern Cooperative Oncology Group performance status more than 1 was associated with an increased risk of hospitalization or death (OR = 1.78, CI: 1.04–3.05, p = 0.04). A delay in cancer care was experienced in 56.4% of the patients.
Table 3.
Multivariable Logistic Analysis of Effect on Composite Outcome of Hospitalization, or Death
| Variables | Effect | 95% Confidence Interval | Chi-Square Test | p Value | Global p |
|---|---|---|---|---|---|
| Vaccinated with booster vs. not vaccinated | 0.30 | 0.15–0.57 | 13.02 | 0.01 | 0.0007 |
| Vaccinated without booster vs. not vaccinated | 0.64 | 0.33–1.24 | 1.74 | 0.19 | — |
| Age 65 y or higher | 0.87 | 0.55–1.36 | 0.39 | 0.53 | — |
| At least 1 comorbidity | 0.98 | 0.60–1.57 | 0.01 | 0.92 | — |
| Active or history of smoking | 1.02 | 0.62–1.66 | 0.01 | 0.95 | — |
| ECOG ≥2 | 1.78 | 1.04–3.05 | 4.43 | 0.04 | — |
ECOG, Eastern Cooperative Oncology Group.
Discussion
In this analysis of the fourth COVID-19 wave, overall mortality of patients with thoracic malignancies in the TERAVOLT database was notably lower at 3.2% compared with 24.2% to 33% in prior surges.1,2 This improvement in mortality is similar to that reported for the general population, with an analysis of patients hospitalized in South Africa with COVID-19 revealing a mortality of 2.7% in wave 4 compared with 19.7% in wave 1 (ancestral variant) and 29.1% in wave 3 (delta).5
Our analysis reveals the importance of a booster vaccination to achieve the maximum protective effect from severe COVID-19 outcomes, including hospitalization or death (relative risk = 0.30) in patients with thoracic cancer. In our analysis, vaccination without booster versus unvaccinated trended toward a protective effect with relative risk of 0.64, though it did not meet statistical significance (CI: 0.33–1.24, p = 0.19). The protective effect of a booster observed in this analysis is reflective of the humoral response found to two or three vaccine doses in both the thoracic malignancy population and a broader population receiving anticancer therapy.7,8,10 In the general population, the adjusted OR of symptomatic COVID-19 for three doses of Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 versus unvaccinated was 0.33 (95% CI: 0.31–0.35) for Omicron and 0.065 (95% CI: 0.059–0.071) for Delta.11 With this knowledge, we should continue to advocate for our patients to receive booster vaccinations to protect this vulnerable population.
Despite COVID-19–related mortality being lower with this wave, more than half (56.4%) of the patients included in this analysis experienced a delay in their cancer care which may lead to a future increase in cancer mortality. The data obtained from this study may suggest that there is no need to delay oncology treatments in patients who have been vaccinated and have also had the booster. New trials are warranted to confirm this hypothesis.
The variant type was unknown for almost two-thirds of the patients in this analysis, which limits the ability to generalize the results specifically toward the Omicron wave. Nevertheless, given the time frame of the diagnosis (on or after November 1, 2021) and the virulence of Omicron, we assumed that most of the infections were Omicron, consistent with the general variant predominance at the time.12 In the patients where the variant type was known (n = 79), 82% had Omicron compared with 14% who had Delta suggesting Omicron was the dominant variant during this time frame.
Another limitation of this study is that further characterization of the delay of cancer care is unknown. The severity of delay may range from a delay in long-term surveillance imaging to initiation of curative intent therapy. Further studies are needed to characterize the impact on therapy delays on cancer-related mortality for patients. An additional limitation of this study is that the primary reason for hospitalization was not further characterized. Many patients in the Omicron wave were found on admission to have an asymptomatic COVID-19 infection, and this was not reflected in our analysis. Furthermore, given the sample size and low mortality, we were not powered to look at risk factors for death alone.
Our analysis suggests that vaccination with booster is protective against severe outcomes of COVID-19 infection, highlighting the importance of continued efforts to improve vaccination and booster rates in patients with thoracic malignancies while ensuring continuity of cancer care. Further research to characterize the effect on cancer-related mortality related to COVID-19 infection is necessary to minimize the impact of the pandemic on our patients.
CRediT Authorship Contribution Statement
Marina Chiara Garassino, Valter Torri, Jennifer G. Whisenant, Christine M. Bestvina, Alessio Cortellini: Conceptualization, Methodology.
Valter Torri: Software Validation, Visualization.
Valter Torri, Jennifer G. Whisenant: Formal analysis.
Valter Torri, Jennifer G. Whisenant, Marina Chiara Garassino, Baena, Christine M. Bestvina: Investigation, Resources.
Christine M. Bestvina, Jennifer G. Whisenant, Heather Wakelee, Elisa Roca, Alessandro De Toma, Fred R. Hirsch, Hirva Mamdani, Balazs Halmos, Oscar Arrieta, Anne-Cecile Metivier, Mary J. Fidler, Jacobo Rogado, Carolyn J. Presley, Celine Mascaux, Carlo Genova, Juan Bautista Blaquier, Alfredo Addeo, Giovanna Finocchiaro, Hina Khan, Julien Mazieres, Floriana Morgillo, Jair Bar, Avinash Aujayeb, Giannis Mountzios, Vieri Scotti, Federica Grosso, Erica Geraedts, Ardak N. Zhumagaliyeva, Marina Chiara Garassino, Javier Baena: Data Curation.
Christine M. Bestvina, Jennifer G. Whisenant, Valter Torri, Alessio Cortellini, Heather Wakelee, Solange Peters, Elisa Roca, Alessandro De Toma, Fred R. Hirsch, Hirva Mamdani, Balazs Halmos, Oscar Arrieta, Anne-Cecile Metivier, Mary J. Fidler, Jacobo Rogado, Carolyn J. Presley, Celine Mascaux, Carlo Genova, Juan Bautista Blaquier, Alfredo Addeo, Giovanna Finocchiaro, Hina Khan, Julien Mazieres, Floriana Morgillo, Jair Bar, Avinash Aujayeb, Giannis Mountzios, Vieri Scotti, Federica Grosso, Erica Geraedts, Ardak N. Zhumagaliyeva, Leora Horn, Marina Chiara Garassino, Javier Baena: Writing - review & editing.
Christine M. Bestvina, Valter Torri, Jennifer G. Whisenant, Marina Chiara Garassino: Writing - original draft.
Marina Chiara Garassino, Jennifer G. Whisenant: Supervision.
Jennifer G. Whisenant: Project administration.
Jennifer G. Whisenant, Marina Chiara Garassino, Leora Horn: Funding acquisition.
Acknowledgments
This study was awarded a grant from the Lung Ambition that supported database development and maintenance. All authors read and approved the submitted version of the manuscript (and any substantially modified version that involves the author's contribution to the study). Each author have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.
Footnotes
Disclosure: Dr. Bestvina declares receiving personal consulting fees from AstraZeneca, Bristol-Myers Squibb, CVS, Genentech, Jazz, Johnson & Johnson, Novartis, Pfizer, Regeneron/Sanofi, Seattle Genetics, and Takeda; receiving speaker bureau fees for Merck; and having institutional contracted research from AstraZeneca and Bristol-Myers Squibb. Dr. Whisenant reports receiving support for this research from International Association for the Study of Lung Cancer/Lung Ambition Alliance and personal royalties/licenses from Anasys Instruments. Dr. Cortellini reports receiving speaker fees/grant consultancies from AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Eisai, and Novartis. Dr. Wakelee reports receiving research funding to the institution from ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, Bristol-Myers Squibb, Clovis Oncology, Genentech/Roche, Merck, Novartis, SeaGen, Xcovery, and Helsinn; compensated advisory board work from AstraZeneca, Janssen, Daiichi Sankyo, Blueprint, and Mirati; and uncompensated advisory board work for Merck and Genentech/Roche. Dr. Peters served as consultant/advisory board member for AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, Foundation Medicine, Illumina, Imedex, IQVIA, Incyte, Janssen, Medscape, Merck Sharp & Dohme, Merck Serono, Merrimack, Novartis, OncologyEducation, Pharma Mar, Phosplatin Therapeutics, PER, Pfizer, PRIME, Regeneron, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, and Takeda; reports receiving speaker fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, ecancer, Eli Lilly, Illumina, Imedex, Medscape, Merck Sharp & Dohme, Novartis, PER, Pfizer, Prime, Roche/Genentech, RTP, Sanofi, and Takeda; and receiving grants/research supports from (sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, GlaxoSmithKline, Illumina, Eli Lilly, Merck Sharp & Dohme, Merck Serono, Mirati, Novartis, Pfizer, Phosplatin Therapeutics, and Roche/Genentech (all to institution). Dr. De Toma reports receiving personal payment from AstraZeneca. Dr. Hirsch reports receiving personal consulting fees from Bristol-Myers Squibb, AstraZeneca/Daiichi, Sanofi/Regeneron, Novartis, Merck, Amgen, and OncoCyte. Dr. Mamdani reports receiving personal consulting fees from Zentalis and personal payments from AstraZeneca. Dr. Halmos reports receiving grants or contracts from AstraZeneca, Merck, Bristol-Myers Squibb, Novartis, Amgen, Mirati, Pfizer, Advaxis, GlaxoSmithKline, TPT, Apollomics, Genentech, Takeda, Daiichi, and Beigene; personal consulting fees from AstraZeneca, Bristol-Myers Squibb, Pfizer, Beigene, Mirati, Janssen, Merck, Takeda, Boehringer Ingelheim, and Veracyte. Dr. Arrieta reports receiving institutional grants and contracts from AstraZeneca, Merck, and Roche; personal payments from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Pfizer, and Roche. Dr. Metivier reports receiving personal payment for expert testimony from Merck Sharp & Dohme, Novartis, and Takeda. Dr. Fidler reports receiving consulting fees from Silverback, G1 Therapeutics, AstraZeneca, Rakuten, Beigene, and Daiichi; speakers bureau from Beigene and Jazz; and research support from Biodesix, Pfizer/EMD Serono, AstraZeneca, Jounce, CytomX Therapeutics, Merck, Novartis, Rakuten, and Alkermes. Dr. Rogado reports receiving personal fees from Roche, AstraZeneca, Merck, Ferrer, Persan Farma, and Fresenius Kabi; travel expenses from Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, and AstraZeneca; and advisor consultancies from Fresenius Kabi. Dr. Mascaux reports receiving personal consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Kephren, Merck Sharp & Dohme, Pfizer, Roche, Sanofi, Takeda, and Janssen; receiving support for travel from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, and Roche; and having European Patent Application EP19305434.3. Dr. Genova reports receiving personal honoraria for presentations from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Roche, and Takeda. Dr. Addeo reports receiving consulting fees from AstraZeneca, Bristol-Myers Squibb, Pfizer, Janssen, Merck, Takeda, Roche, Amgen, Novartis, and Sanofi. Dr. Khan reports receiving study funding by the Bristol-Myers Squibb Foundation (BMSF) for Diversity in Clinical Trials and having participated to advisory boards for Sanofi Genzyme. Dr. Mazieres reports receiving personal fees from Merck, AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Novartis, Daiichi, and Pfizer; and grants from Roche, AstraZeneca, and Pierre Fabre. Dr. Bar reports receiving institutional research grants from AstraZeneca, Takeda, OncoHost, ImmuneAI, Merck Sharp & Dohme, Roche, Eli Lilly, ICRF, and Tel-Aviv University; receiving personal consulting fees from Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, AstraZeneca, Novartis, Pfizer, Causalis, Bayer, and Takeda; having participation in an advisory board for Roche and AstraZeneca; having a leadership role in the Lung Ambition Alliance—Israel; and having stock/stock options in Causalis. Dr. Mountzios reports receiving grants or contracts from AstraZeneca, Bristol-Myers Squibb, Amgen, Gilead Pharmaceuticals, GlaxoSmithKline, Immunomedics, Merck, Merck Sharp & Dohme, Novartis, Roche, and Sanofi; consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, and Takeda; and support for meetings/travel from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme, Roche, Sanofi, and Takeda. Dr. Scotti reports receiving consulting fees from Roche and Boehringer Ingelheim; personal payments from AstraZeneca, Takeda, Bristol-Myers Squibb, Merck Sharp & Dohme, Daiichi Sankyo, Boehringer Ingelheim, Roche, Pfizer, and Novartis; participation in an advisory board from AstraZeneca, Takeda, Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Pfizer, and Novartis. Dr. Grosso reports receiving personal fees for advisory role, speaker engagements, and travel and accommodation expenses from Merck Sharp & Dohme, Novocure, Bristol Myer Squibb, Boehringer Ingelheim, Pharmamar, and Novartis; personal fees and travel support from Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Novocure, and Pharmamar; speakers bureau for Novocure; and honoraria for educational events from Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, and Novartis. Dr. Horn reports employment from AstraZeneca. Dr. Garassino reports receiving grants and research support to the institution from Eli Lilly, Merck Sharp & Dohme, Pfizer (MISP), AstraZeneca, Merck Sharp & Dohme International GmbH, Bristol-Myers Squibb, Boehringer Ingelheim Italia S.p.A, Celgene, Eli Lilly, Ignyta, Incyte, MedImmune, Novartis, Pfizer, Roche, Takeda, Tiziana, Foundation Medicine, GlaxoSmithKline, and Spectrum Pharmaceuticals; personal consulting fees from AstraZeneca, Merck Sharp & Dohme International GmbH, Bristol-Myers Squibb, Boehringer Ingelheim Italia S.p.A, Celgene, Eli Lilly, Ignyta, Incyte, Inivata, MedImmune, Novartis, Pfizer, Roche, Takeda, Seattle Genetics, 1 Mirati, Daiichi Sankyo, Regeneron, and Merck; speaker fees from AstraZeneca, Merck Sharp & Dohme, and Takeda; and travel and accommodation expenses from Roche. Dr. Espinar reports receiving personal fees from AstraZeneca, Bristol-Myers Squibb, and Roche and nonfinancial support from Angelini. All the declared conflict of interests are outside the submitted work. The remaining authors declare no conflict of interest.
Cite this article as: Bestvina CM, Whisenant JG, Torri V, et al. Coronavirus disease 2019 outcomes, patient vaccination status, and cancer-related delays during the Omicron wave: a brief report from the TERAVOLT analysis. JTO Clin Res Rep. 2022;3:100335.
References
- 1.Garassino M.C., Whisenant J.G., Huang L.C., et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21:914–922. doi: 10.1016/S1470-2045(20)30314-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Whisenant J.G., Baena J., Cortellini A., et al. A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry. J Thorac Oncol. 2022;17:661–674. doi: 10.1016/j.jtho.2021.12.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.World Health Organization Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
- 4.Cao Y., Wang J., Jian F., et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657–663. doi: 10.1038/s41586-021-04385-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Maslo C., Friedland R., Toubkin M., Laubscher A., Akaloo T., Kama B. Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 omicron wave compared with previous waves. JAMA. 2022;327:583–584. doi: 10.1001/jama.2021.24868. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Tartof S.Y., Slezak J.M., Fischer H., et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398:1407–1416. doi: 10.1016/S0140-6736(21)02183-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Fenioux C., Teixeira L., Fourati S., et al. SARS-CoV-2 antibody response to 2 or 3 doses of the BNT162b2 vaccine in patients treated with anticancer agents. JAMA Oncol. 2022;8:612–617. doi: 10.1001/jamaoncol.2021.7777. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Gounant V., Ferré V.M., Soussi G., et al. Efficacy of severe acute respiratory syndrome Coronavirus-2 vaccine in patients with thoracic cancer: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses. J Thorac Oncol. 2022;17:239–251. doi: 10.1016/j.jtho.2021.10.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Williamson E.J., Walker A.J., Bhaskaran K., et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. doi: 10.1038/s41586-020-2521-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Shroff R.T., Chalasani P., Wei R., et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021;27:2002–2011. doi: 10.1038/s41591-021-01542-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Accorsi E.K., Britton A., Fleming-Dutra K.E., et al. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 omicron and delta variants. JAMA. 2022;327:639–651. doi: 10.1001/jama.2022.0470. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Centers for Disease Control and Prevention COVID data tracker: variant proportions. https://covid.cdc.gov/covid-data-tracker/#variant-proportions